Digests

Decision Information

Decision Content

PATENTS

Judicial review of decision Canadian Patent 2296726 (′726) not meeting requirements of Patented Medicines (Notice of Compliance) Regulations, s. 4(2)(b), ineligible for listing on patent register—Minister’s interpretation of s. 4(2)(b) correct —Supported by Eli Lilly Canada Inc. v. Canada (Minister of Health), [2003] 3 F.C. 140 (C.A.)—′726 patent, active ingredient of which is amlodipine besylate, not extending to include combination of amlodipine, atorvastatin calcium— Invention relating to combinations and their uses, thus excluding amlodipine besylate alone—Combinations also explicitly excluding atorvastatin—Application dismissed— Patented Medicines (Notice of Compliance) Regulations, SOR/93‑133, s. 4(2)(b).

Pfizer Canada Inc. v. Canada (Minister of Health) (T‑283‑05, 2006 FC 210, Campbell J., order dated 16/2/06, 29 pp.)

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.